v3.26.3
Schedule of Financial Information by Segment (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Segment Reporting [Line Items]    
Net revenues $ 3,846 $ 11,426
Cost of revenues (excluding amortization of acquired intangible assets) 1,452 3,554
Direct expenses 12,159 17,990
Segment contribution (9,765) (10,118)
Indirect expenses 368 [1] 368 [2]
Loss from operations (10,133) (10,486)
Other income (expenses) 11,007 (9,268)
Loss before income taxes 874 (19,754)
Cell Therapy [Member]    
Segment Reporting [Line Items]    
Net revenues 493 264
Cost of revenues (excluding amortization of acquired intangible assets)  
Direct expenses 2,467 3,257
Segment contribution (1,974) (2,993)
Biobanking [Member]    
Segment Reporting [Line Items]    
Net revenues 1,250 1,408
Cost of revenues (excluding amortization of acquired intangible assets) 222 209
Direct expenses 243 369
Segment contribution 785 830
Degenerative Disease [Member]    
Segment Reporting [Line Items]    
Net revenues 2,103 9,754
Cost of revenues (excluding amortization of acquired intangible assets) 1,230 3,345
Direct expenses 1,588 4,747
Segment contribution (715) 1,662
Other [Member]    
Segment Reporting [Line Items]    
Net revenues
Cost of revenues (excluding amortization of acquired intangible assets)
Direct expenses 7,861 9,617
Segment contribution $ (7,861) $ (9,617)
[1] Comprised of amortization of intangible assets.
[2] Comprised of amortization of intangible assets.